Dacogen

Dacogen is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Dacogen incorporate it into DNA during replication and RNA during transcription. The incorporation of Dacogen into DNA or RNA inhibits methyltransferase thereby causing demethylation in that sequence. This adversely affects the way that cell regulatory proteins are able to bind to the DNA/RNA substrate.

Dacogen - Pharmacology:

Dacogen is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation or apoptosis. Dacogen inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Dacogen-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine.

Dacogen mini report

Dacogen NDA
NDA - A product marketed under an approved New Drug Application
Dacogen INTRAVENOUS
INTRAVENOUS
Dacogen INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Dacogen HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Start - Stop data
START DATA:
1996-May-03
Start - Stop data
STOP DATA
not occurred

Dacogen for patients

Patients should inform their physician about any underlying liver or kidney disease.

Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Dacogen.

Men should be advised not to father a child while receiving treatment with Dacogen, and for 2 months afterwards.

Dacogen Interactions

Drug interaction studies with decitabine have not been conducted. In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes. In vitro metabolism studies have suggested that decitabine is not a substrate for the human liver cytochrome P450 enzymes. As plasma protein binding of decitabine is negligible (<1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.

Dacogen Contraindications

Dacogen is contraindicated in patients with a known hypersensitivity to decitabine.

Generic name, Overdose, Half Life Dacogen, Food Interactions, Chemical, etc..

Dacogen see also FDA report


Chemical structure:
+ N _ N O N O N O O H H H H H H H H H H H H C8H12N4O4 2D chemical structure C8H12N4O4 SVG | 2D structure Decitabine chemical names, chemical properties, classification C8H12N4O4